Bausch Health's Phase 3 RED-C Clinical Program Fails Primary Endpoint for Liver Cirrhosis Drug
BHC sits 39% above its 52-week low of $4.25 on elevated volume (3.0× avg).
Summary
Bausch Health announced that its Phase 3 RED-C clinical program for amorphous-rifaximin SSD failed to meet its primary endpoint, representing a significant pipeline setback.
Key Events · Product Development and Regulatory · BHC
-
Phase 3 Clinical Program Failure
The global Phase 3 RED-C clinical program, evaluating amorphous-rifaximin solid soluble dispersion for the primary prevention of hepatic encephalopathy in liver cirrhosis patients, did not meet its primary endpoint in both trials.
-
Impact on Pipeline
This represents a significant setback for Bausch Health's product pipeline, as the drug was targeting a condition with no currently approved treatments, indicating a loss of a potential future revenue stream.
-
CEO Disappointment
CEO Thomas J. Appio expressed disappointment in the results and stated the company is reviewing the full dataset to determine potential new development opportunities.
-
Contrasts Recent Positive News
This negative development follows recent positive announcements, including the company's expectation to reaffirm its full-year 2025 guidance at the higher end and a successful $2.8 billion refinancing by its Bausch + Lomb subsidiary earlier this month.
Analysis · BHC · Life Sciences
Bausch Health announced the failure of its global Phase 3 RED-C clinical program for amorphous-rifaximin solid soluble dispersion, a drug aimed at preventing hepatic encephalopathy in adults with liver cirrhosis. This is a significant setback for the company's pipeline, as the drug did not meet its primary endpoint despite being safe and well-tolerated. The CEO expressed disappointment, highlighting the lack of approved treatments for these patients. This negative development contrasts with recent positive news, including reaffirming 2025 guidance and a successful $2.8 billion refinancing by its subsidiary Bausch + Lomb. Investors should monitor the company's review of the full dataset for any potential new development opportunities, but the immediate impact is a loss of a significant potential revenue stream.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHC was trading at $5.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $4.25 to $8.69. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.